文献速递治疗药物监测与药物基因组学

STRATIfy-PK评分:预测抗TNF治疗患者药代动力学失败风险的工具

STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient.
PubMed 文献 · Br J Clin Pharmacol · 2025-11-21

本研究基于457例接受英夫利西单抗(IFX)或阿达木单抗(ADA)治疗的免疫介导炎症性疾病患者,回顾性分析1035份治疗药物监测(TDM)样本,识别药代动力学失败(免疫原性或亚治疗浓度)的风险因素,并开发预测模型STRATIfy-PK SCORE。模型对免疫原性预测的AUC为0.795-0.800,对亚治疗浓度的AUC为0.686-0.700,校准良好。该评分有助于早期识别高风险患者并支持主动个体化TDM策略。

要点

  • STRATIfy-PK评分可预测抗TNF药物的免疫原性和亚治疗浓度风险。
  • 免疫原性预测模型AUC为0.795-0.800,亚治疗浓度模型AUC为0.686-0.700。
  • 既往低诱导或维持浓度、早期TDM、单药治疗等是重要预测因素。

核心结论

  • STRATIfy-PK评分能早期识别抗TNF治疗患者药代动力学失败高风险,可能支持主动个体化TDM策略以改善临床结局。

研究设计与样本

  • 回顾性队列研究,纳入457例接受IFX或ADA治疗的成人免疫介导炎症性疾病患者,分析1035份TDM样本。
  • 药代动力学失败定义为出现抗药抗体或基于适应症特异性治疗阈值的亚治疗血清浓度。
  • 分别针对每种药物和结局建立多变量逻辑回归模型,采用AUC和校准图评估模型性能。

主要发现

  • 亚治疗药物浓度发生于59.7%的患者,免疫原性发生率为18.8%。
  • IFX免疫原性预测因素包括既往低诱导或维持浓度、强直性脊柱炎和类风湿关节炎。
  • ADA免疫原性预测因素包括不依从、既往低维持浓度、早期TDM、单药治疗和风湿诊断。
  • IFX亚治疗浓度预测因素包括既往低维持浓度、早期TDM、高炎症负荷和类风湿关节炎;ADA亚治疗浓度预测因素包括既往低维持浓度、强直性脊柱炎和早期TDM。
  • 模型对免疫原性预测的AUC为0.795-0.800,对亚治疗浓度的AUC为0.686-0.700,校准良好。

临床怎么用

  • 临床可应用STRATIfy-PK评分早期识别抗TNF治疗药代动力学失败高风险患者,并考虑主动个体化TDM策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study is to identify risk factors associated with pharmacokinetic failure, defined as immunogenicity or subtherapeutic drug concentrations, in patients treated with infliximab (IFX) or adalimumab (ADA), and to develop a predictive model (STRATIfy-PK SCORE) to support proactive therapeutic drug monitoring (TDM). METHODS: A retrospective cohort study was conducted in adult patients with immune-mediated inflammatory diseases receiving IFX or ADA. Pharmacokinetic failure was defined by anti-drug antibodies or subtherapeutic serum concentrations, based on indication-specific therapeutic thresholds. Multivariate logistic regression models were developed separately for each drug and outcome. Model performance was assessed using area under the receiver operating characteristic curve (AUC) and calibration plots. RESULTS: Of 457 patients (298 ADA, 159 IFX), 1035 TDM samples were analysed. Subtherapeutic drug concentrations occurred in 59.7% of patients, and immunogenicity was observed in 18.8%. In IFX-treated patients, predictors of immunogenicity included prior low induction or maintenance levels, ankylosing spondylitis and rheumatoid arthritis. For ADA, predictors were non-adherence, prior low maintenance levels, early TDM, monotherapy and rheumatic diagnoses. Predictors of subtherapeutic concentrations included prior low maintenance levels, early TDM, high inflammatory burden, and rheumatoid arthritis for IFX, and prior low maintenance levels, ankylosing spondylitis and early TDM for ADA. Predictive models demonstrated good discriminative performance (AUC 0.795-0.800 for immunogenicity; 0.686-0.700 for subtherapeutic levels) and satisfactory calibration. CONCLUSIONS: STRATIfy-PK SCORE allows early identification of patients at high risk of pharmacokinetic failure and may support proactive, personalized TDM strategies to improve clinical outcomes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Iniesta-Navalón C, Ríos-Saorín M, Rentero-Redondo L, et al. STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient. Br J Clin Pharmacol. 2025. PMID: 41268891. doi:10.1002/bcp.70346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。